Development of PI3K inhibitors: lessons learned from early clinical trials
Top Cited Papers
- 12 February 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 10 (3), 143-153
- https://doi.org/10.1038/nrclinonc.2013.10
Abstract
No abstract availableKeywords
This publication has 110 references indexed in Scilit:
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Molecular prescreening to select patient population in early clinical trialsNature Reviews Clinical Oncology, 2012
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate CancerCancer Cell, 2011
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and ActivityCancer Cell, 2011
- Clinical Development of Phosphatidylinositol-3 Kinase Pathway InhibitorsCurrent Topics in Microbiology and Immunology, 2010
- AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human CancerCancer Cell, 2009
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2009
- Should individual PI3 kinase isoforms be targeted in cancer?Current Opinion in Cell Biology, 2009
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006